Metabolic syndrome: Nature, therapeutic solutions and options

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 12, 2011, Pages 1887-1900

  Onat, Altan ^a,b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Nisbetiye Cad 59/24   (Turkey)

Author keywords

Abdominal obesity; Atherogenic dyslipidemia; Cardiovascular disease risk; Diabetes mellitus; HDL dysfunction; Metabolic syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ALCOHOL CONSUMPTION; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPOPROTEINEMIA; EXERCISE; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; RISK FACTOR; SMOKING CESSATION; WEIGHT CONTROL;

EID: 79960452600     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.585462     Document Type: Review

References (127)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607 (Pubitemid 19004941)
2. Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adullts. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adullts. (Adult Treatment Panel III). JAMA 2001;285:2486-97
3. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13-18
4. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-62 (Pubitemid 41338752)
5. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
6. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Rep 2009;5:1-7
7. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76 (Pubitemid 38668985)
8. Onat A, Ceyhan K, Basar O, et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-9
9. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract 2007;77:251-7 (Pubitemid 46671653)
10. Weng X, Liu Y, Ma J, et al. An urban-rural comparison of the prevalence of the metabolic syndrome in Eastern China. Public Health Nutr 2007;10:131-6 (Pubitemid 46682330)
11. Duncan GE, Li SM, Zhou XH. Prevalence and trends of a metabolic syndrome phenotype among US adolescents, 1999-2000. Diabetes Care 2004;27:2438-43 (Pubitemid 39281398)
12. Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents-an IDF consensus report. Pediatr Diabetes 2007;8:299-306 (Pubitemid 47422902)
13. Onat A, Hergenc G, Can G. Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition. Anadolu Kardiyol Derg 2007;7:31-6
14. Gami AS, Witt BJ, Howard DE. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14 (Pubitemid 46135879)
15. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7 (Pubitemid 30430551)
16. Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-6 (Pubitemid 37498976)
17. van Acker BAC, Botma G-J, Zwinderman AH, et al. REGRESS Study Group. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesterol ester transfer protein and hepatic lipase gene variants. Atherosclerosis 2008;200:161-7
18. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42 (Pubitemid 351186873)
19. Onat A, Can G, Ayhan E, et al. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009;58:1393-9
20. Onat A, Hergenc G, Bulur S, et al. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010;142:72-9
21. Than TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-21 (Pubitemid 41071061)
22. Laaksonen DE, Niskanen L, NyyssOnen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47:1403-10
23. Onat A, Can G, Hergenc G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism 2008;57:207-14
24. Onat A, Ozhan H, Erbilen E, et al. Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels. Int J Cardiol 2009;135:211-17
25. Onat A, Can G, Hergenc G, et al. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension, diabetes, independent of markers of central obesity and inflammation. Int J Obes (Lond) 2007;31:1119-25 (Pubitemid 46987762)
26. Onat A, Hergenc G, Ayhan E, et al. Serum apolipoprotein E concentrations among Turks: Additive information to genotype relative to dyslipidemia and metabolic syndrome. Arch Turk Soc Cardiol 2007;35:449-57 (Pubitemid 351309391)
27. Onat A, Hergenc G, Can G, et al. Complement C3: a determinant of cardiometabolic risk, additive to metabolic syndrome, in middle-aged population. Metabolism 2010;59:628-34
28. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyl transferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27:1427-32 (Pubitemid 38679993)
29. Onat A, Hergenc G, Karabulut A, et al. Serum gamma glutamyltransferase as a marker of metabolic syndrome and coronary disease likelihood in nondiabetic middle-aged and elderly adults. Prev Med 2006;43:136-9 (Pubitemid 44175542)
30. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007;27:127-33 (Pubitemid 46360389)
31. Onat A, Hergenc G, Uyarel H, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006;19:1055-62 (Pubitemid 44485960)
32. Costa A, Iguala I, Bedini J, et al. Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome. Metabolism 2002;51:372-5 (Pubitemid 34232641)
33. Lin JP, O'Donnell CJ, Schwaiger JP, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006;114:1476-81 (Pubitemid 44527002)
34. Giral P, Ratziu V, Couvert P, et al. Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis 2010;210:607-13
35. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007;27:1411-16 (Pubitemid 46823453)
36. Onat A, Hergenc G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011;60:499-512
37. Onat A, Hergenc G, Ayhan E, et al. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor among Turks. Diabet Med 2009;26:981-8
38. Corsetti JP, Zareba W, Moss AJ, et al. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 2006;187:191-7 (Pubitemid 43817014)
39. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19 (Pubitemid 36935533)
40. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107:391-7
41. Ford ES. The metabolic syndrome and mortality from cardiovascular diseaseand all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173:309-14 (Pubitemid 38469801)
42. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the Health, Aging, and Body Composition cohort. Diabetes 2004;53:1068-73 (Pubitemid 38436620)
43. Katzmarzyck PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004;164:1092-7 (Pubitemid 38668988)
44. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in the United States. Circulation 2004;110:1245-50 (Pubitemid 39202340)
45. Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-7 (Pubitemid 35396938)
46. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008;31:1898-904
47. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type-2 diabetes: the San Antonio Heart study. Diabetes Care 2003;26:3153-9 (Pubitemid 37339513)
48. Hanley AJ, Karter AJ, Williams K, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005;112:3713-21 (Pubitemid 43739511)
49. Schmidt MI, Duncan BB, Bang H, et al. Atherosclerosis Risk in Communities Investigators. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005;28:2013-18 (Pubitemid 41060977)
50. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9
51. KOmurcu-Bayrak E, Onat A, Poda M, et al. Gender-modulated impact of apolipoprotein A5 gene (APOA5)-1131T>C and c.56C>G polymorphisms on lipids, atherogenic dyslipidemia and metabolic syndrome in Turkish adults. Clin Chem Lab Med 2008;46:778-84 (Pubitemid 351821636)
52. O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008;51:249-55
53. Ceriello A, Assaloni R, Ros RD, et al. Effect of atorvastatin and irbesartan, alone and in combination, on post-prandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005;111:2518-24 (Pubitemid 40696141)
54. Bansal S, Buring J, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16 (Pubitemid 47080485)
55. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308 (Pubitemid 47080484)
56. Monnier L, Mas E, Ginet C, et al. Association of oxidative stress by acute glucose fluctuations compared with sustained hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7
57. Lichtenstein A, Appel L, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96 (Pubitemid 44305278)
58. Vrolix R, Mensink RP. Effects of glycemic load on metabolic risk markers in subjects at increased risk of developing metabolic syndrome. Am J Clin Nutr 2010;92:366-74
59. Jenkins D, Kendall C, Faulkner D, et al. Long-term effects of a plant-based dietary portfolio of cholesterol-lowering foods on blood pressure. Eur J Clin Nutr 2007;62:781-8
60. Mitrou PN, Kipnis V, Thiebaut AC, et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med 2007;167:2461-8 (Pubitemid 350254905)
61. Hlebovicz J, Darwiche G, Bjorgell O, Almer L-O. Effects of cinnamon on post-prandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J Clin Nutr 2007;85:1552-6 (Pubitemid 46890423)
62. Arora S, MacFarlane S. The case for low carbohydrate diets in diabetes management. Nutr Metab (Lond) 2005;2:16-24
63. Ma Y, Griffiths J, Chasan-Taber L, et al. Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr 2006;83:760-6 (Pubitemid 44713137)
64. Dandona P, Mohanty P, Ghanim H, et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001;86:355-62 (Pubitemid 32109818)
65. Fontana L, Klein S. Aging, adiposity, and calorie restriction. JAMA 2007; 297: 986-94 (Pubitemid 46380237)
66. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999;319:1523-8
67. Di Castelnuovo A, Rotondo S, Iacoviello L, et al. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002;105:2836-44 (Pubitemid 34666095)
68. Di Castelnuovo A, Costanzo S, Bagnardi V, et al. Alcohol dosing and total mortality in men and women: an up-dated meta-analysis of 34 prospective studies. Arch Intern Med 2006;166:2437-45 (Pubitemid 44913227)
69. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993;329:1829-34 (Pubitemid 23360481)
70. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63 (Pubitemid 23164134)
71. Onat A, Hergenc G, Dursunoglu D, et al. Associations of alcohol consumption with blood pressure, lipoproteins and subclinical inflammation among Turks. Alcohol 2008;42:593-601
72. Onat A, Hergenc G, Kucukdurmaz Z, et al. Moderate and heavy alcohol consumption among Turks: Long-term impact on mortality and cardiometabolic risk. Turk Kardiyol Dern Ars 2009;37:83-90
73. Levine J. Exercise: a walk in the park? Mayo Clin Proc 2007;82:797-8 (Pubitemid 47015456)
74. Healy G, Dunstan D, Salmon J, et al. Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose. Diabetes Care 2007;30:1384-9 (Pubitemid 46871142)
75. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002;347:1483-92 (Pubitemid 35257587)
76. Kay SJ, Fiatorone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev 2006;7:183-200
77. Church TS, Barlow CE, Ernest CP, et al. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 2002;22:1869-76 (Pubitemid 35315775)
78. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type-2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50 (Pubitemid 32378388)
79. Rimm EB, Manson JE, Stampfer MJ, et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 1993;83:211-14 (Pubitemid 23046478)
80. Hu FB, Manson J, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-7
81. Will JC, Galuska DA, Ford ES, et al. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol 2001;30:540-6 (Pubitemid 32600247)
82. Chiolero A, Jacot-Sadowski I, Faeh D, et al. Association of cigarettes smoked daily with obesity in a general adult population. Obesity (Silver Spring) 2007;15:1311-18 (Pubitemid 46932487)
83. Onat A, Ozhan H, Esen AM, et al. Prospective epidemiologic evidence of a 'protective' effect of smoking on metabolic syndrome and diabetes among Turkish women-without associated overall health benefit. Atherosclerosis 2007;193:380-9
84. Onat A, Ayhan E, Hergenc G, et al. Smoking inhibits visceral fat accumulation in Turkish females: relation of visceral fat and body fat mass to atherogenic dyslipidemia, inflammatory markers, insulin resistance and blood pressure. Metabolism 2009;58:963-70
85. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. Consensus Conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;51:1512-24 (Pubitemid 351470037)
86. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959-64 (Pubitemid 29183891)
87. The Coronary Drug Project Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81
88. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55 (Pubitemid 17208898)
89. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162:1568-76 (Pubitemid 34765005)
90. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT Study: a randomized trial: Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263-70
91. Rajpathak SN, Kumbhani DJ, Krandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9
92. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:738-42
93. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170:1024-31
94. Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ‡ 5% or Framingham risk > 20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J 2011;32:75-83
95. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
96. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45 (Pubitemid 17147964)
97. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
98. Asztalos BF, Collins D, Horvath KV, et al. Relation of gemfibrozil treatment and high-density lipoprotein (HDL) subpopulation profile with cardiovascular events in the Veterans Affairs HDL Intervention Trial (VA-HIT). Metabolism 2008;57:77-83 (Pubitemid 350234976)
99. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
100. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
101. Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother 2011;12:13-30
102. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011;97:350-6
103. Thiess F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet 2003;361:477-85 (Pubitemid 36173713)
104. Ebbesson SOE, Roman MJ, Devereux RB, et al. Consumption of omega-3 fatty acids is not associated with a reduction in carotid atherosclerosis: the Genetics of Coronary Artery Disease in Alaska Natives study. Atherosclerosis 2008;199:346-53 (Pubitemid 352020410)
105. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55
106. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized, open-label, blinded endpoint analysis. Lancet 2007;369:1090-8 (Pubitemid 46483662)
107. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-72
108. Goldberg RB, Kendall DM, Deeg MA, et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54 (Pubitemid 40923063)
109. Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride/high- density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients. Insights from the PERISCOPE (pioglitazone effect on regression of intravascular sonographic coronary obstruction prospective evaluation) Study. J Am Coll Cardiol 2011;57:153-9
110. Boyko EJ, Gerstein HC, Mohan V, et al. DREAM trial investigators. Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabet Med 2010;27:1226-32
111. DREAM On (diabetes reduction assessment with ramipril and rosiglitazone medication ongoing follow-up) Investigators. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 2011;54:487-95
112. Goldberg AC. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. Am J Cardiol 2004;94:121-7
113. Sanyal S, Kuvin JT, Karas RH. Niacin and laropiprant. Drugs Today (Barc) 2010;46:371-8
114. Olsson AG. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opin Pharmacother 2010;11:1715-26
115. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with duslipidemia. Mayo Clin Proc 2008;83:470-8 (Pubitemid 351536472)
116. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2123-2
117. Stevenson E, Williams C, Mash LE, et al. Influence of high-carbohydrate mixed meals with different glycemic indexes on substrate utilization during subsequent exercise in women. Am J Clin Nutr 2006;84:354-60 (Pubitemid 44699145)
118. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 2006;119(Suppl 1):S3-9
119. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. Cancer Biol Ther 2008;358:1547-59
120. Barzilay JI, Gao P, O'Donnell M, et al. ONTARGET and TRANSCEND Investigators. Albuminuria and decline in cognitive function: the ONTARGET/TRANSCEND studies. Arch Intern Med 2011;171:142-50
121. Scheen AJ. A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide. Rev Med Liege 2010;65:217-23
122. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
123. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic individuals. J Am Coll Cardiol 2008;51:1653-62 (Pubitemid 351626406)
124. Torgerson JS, Hauptman J, Boldrin MN, SjOstrOm L. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004;27:155-61
125. Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007;30:275-32
126. Salpeter SR, Walsh JM, Omiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54 (Pubitemid 44184248)
127. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77 (Pubitemid 46556472)